
    
      This is 12-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle
      (paroxetine mesylate) Capsules 7.5 mg and placebo capsules in subjects with moderate to
      severe postmenopausal VMS, defined as follows:

        -  Moderate VMS: Sensation of heat with sweating, able to continue activity

        -  Severe VMS: Sensation of heat with sweating, causing cessation of activity

      The study is comprised of a screening period, a run-in period, a baseline visit, and a
      double-blind treatment period.
    
  